Rheumatoid arthritis is a chronic joint disease that affects joints of all sizes with a disabling tendency. The affected joints suffer from pathological damage to cartilage, bone, tendons, and accessory structures as a result of synovial inflammation, resulting in joint swelling, pain, and dysfunction. If the inflammation is not effectively controlled in time, the damage will continue to progress and eventually lead to joint deformity. Clinical management of rheumatoid arthritis can vary from mild to severe, early to late. The term “mild” refers to the degree of joint inflammation, ranging from the number of joints involved throughout the body to the degree of swelling and pain in each joint, while the term “early” refers to the degree of joint damage, ranging from mild damage in the early stages to severe damage in the late stages. Many effective drugs, including biologics, have been developed for inflammation, and patients with severe joint symptoms can be relieved and reduced. However, all of these drugs do not directly target the repair of the damage; the damage needs to be repaired by the body’s own functions, and whether the repair is complete depends largely on the extent of the damage. In the early stages of rheumatoid arthritis, the damage is not heavy and easy to repair, but when the damage accumulates, it becomes increasingly difficult to repair. Once the disease enters an advanced stage, even if the inflammation is completely eliminated with drugs, the damage is still difficult to repair completely, and even if anti-inflammatory treatment is maintained, the joint structure will continue to be damaged, eventually causing functional impairment and a decrease in quality of life. Treatment of rheumatoid arthritis in its early stages is very important. The effectiveness of early treatment affects long-term joint function. If the inflammation is not significantly altered in the early stages, joint function can be restored as long as the inflammation is controlled; in the late stages, the joint structure is irreversibly damaged, and even in the absence of inflammation, joint function is still affected by the existing damage, making it difficult to restore the original function. The effectiveness of early treatment is also related to the future use of drugs. Rheumatoid arthritis is a chronic joint disease, and patients usually need to take anti-rheumatic drugs for a long time. Studies have found that most patients who achieve adequate remission early on can reduce their medication dose or even stop taking it altogether for a long time afterwards. For patients, this means that achieving early remission holds the promise of reduced drug dependence and reduced medical expenses. Thus, the value of early remission is definitely greater than late remission, and the benefit of early remission is definitely greater than late remission, so the “best window” for treating rheumatoid arthritis is in its early stages. In the past, there was no standardized time span for the early stages of rheumatoid arthritis, with some defining it as 1 year or 3 years from the onset of joint pain. The latest revision of the American College of Rheumatology’s 2012 guidelines for the treatment of rheumatoid arthritis reached a consensus, based on expert discussion, that the early stage should be within 6 months of the onset of disease. This provides a stricter time frame for the “optimal window” to truly screen and diagnose patients with rheumatoid arthritis who have a good prognosis with minimal damage and are given timely and adequate medication to restore joint function and shorten treatment time. Those who miss this “best window” for treatment not only have no hope for complete restoration of joint function, but also face the dilemma of long-term drug dependence. The six-month time frame is valuable for every patient with new rheumatoid arthritis, and it is imperative that patients and physicians work together to achieve early remission during this period. The most important thing for the patient is to consult with the rheumatologist when symptoms of multiple small joint pains and morning stiffness appear, and to improve serum and imaging tests to clarify the diagnosis as soon as possible. The most important thing for the doctor is to accurately assess the priority of the joint lesion, reasonably select the first treatment drug, closely follow up, and adjust the plan as soon as the treatment is found to be ineffective. Do not miss the valuable “best window” for rheumatoid arthritis treatment due to delayed diagnosis or substandard treatment.